As a result, targeted inhibition of ANGPTL3 using a monoclonal antibody (evinacumab), an antisense oligonucleotide (ASO), and other pharmacologic strategies is an emerging therapeutic approach for treating refractory hyperlipidemia and potentially lowering cardiovascular disease risk. Here, ANGPTL3 is linked to hyperlipidemia.